cGAS-STING and Aging: The DNA Alarm That Fuels Inflammaging

An alarm that was never meant to point inward

Every cell carries a way of recognising danger from the inside. One of the most important is a two-part sensor with an awkward name: cGAS-STING. The first part, cGAS — cyclic GMP-AMP synthase — is an enzyme that patrols the cytoplasm looking for double-stranded DNA. That is a clever place to look, because healthy DNA is supposed to be locked away in the nucleus and inside mitochondria. Loose DNA drifting in the cytoplasm almost always means trouble: a virus has injected its genome, or a bacterium has broken in.

When cGAS grabs that stray DNA, it manufactures a tiny second-messenger molecule called cGAMP (2'3'-cyclic GMP-AMP, chemical formula C₂₀H₂₄N₁₀O₁₃P₂). cGAMP diffuses to the endoplasmic reticulum and switches on the second part of the system, STING (Stimulator of Interferon Genes). Activated STING sets off a signalling cascade that produces type I interferons and inflammatory cytokines — the molecular sirens that summon the immune system.^[5] As a defence against infection, it is elegant and essential. The problem is what happens when the DNA it detects is not a virus, but you.

Why aging cells trip their own sensor

The link between this pathway and aging runs through the mitochondria — the cell's power plants, which carry their own small loops of DNA. Mitochondria become progressively leakier and more damaged with age. When they are stressed, they release mitochondrial DNA (mtDNA) into the cytoplasm, and cGAS cannot tell the difference between mtDNA and a pathogen's genome. It sees misplaced double-stranded DNA and it fires.^[5]

Several age-related changes feed the same problem. Genomic instability sends fragments of nuclear DNA into the cytoplasm. Senescent cells — the dysfunctional, non-dividing cells that accumulate over a lifetime — are especially prone to leaking DNA and to strong cGAS-STING activation, and the pathway is now understood to help drive the inflammatory secretions (the senescence-associated secretory phenotype, or SASP) that make senescent "zombie" cells so corrosive to surrounding tissue.^[2] The result is a self-reinforcing loop: damage releases DNA, DNA activates cGAS-STING, the resulting inflammation causes more damage.

The 2023 Nature study: from marker to driver

For years the open question was whether cGAS-STING activity was a cause of aging decline or merely a symptom of it. A 2023 study in Nature by Gulen, Samson, Ablasser and colleagues at EPFL provided the most decisive answer to date.^[1] Their central finding was causal, not correlational: when they blocked STING in aged mice, the inflammatory signature of old age subsided.

Specifically, STING blockade suppressed the inflammatory phenotype of senescent human cells and tissues, dampened aging-related inflammation across multiple peripheral organs and the brain, and — critically — led to measurable improvement in tissue function.^[1] That last point is what separates a driver from a bystander. If you switch a pathway off and the tissue works better, the pathway was doing harm, not just recording it.

The brain findings were the most striking. The researchers showed that activating STING in the aging brain drove microglia — the brain's resident immune cells — into reactive, inflammatory states, and that this was sufficient to produce neurodegeneration and cognitive decline. The trigger was cytosolic DNA released from perturbed mitochondria in old microglia, which engaged cGAS and pushed the cells into a neurotoxic state that harmed neighbouring neurons and impaired memory.^[1] In a cGAS gain-of-function mouse, dialling the pathway up in microglia alone was enough to reproduce the aging-associated inflammatory state and its damage to memory.^[1]

The inflammaging connection

Chronic, low-grade, sterile inflammation — inflammation without an infection to justify it — is one of the most consistent features of biological aging. Longevity researchers call it inflammaging, and it is statistically tied to cardiovascular disease, neurodegeneration, frailty and mortality. For a long time inflammaging was described mostly at the level of blood markers such as high-sensitivity CRP and interleukin-6, without a clear origin.

cGAS-STING offers one of the cleanest mechanistic explanations for where a large share of that sterile inflammation comes from. A 2025 review in Nature Reviews Immunology catalogues how deeply the pathway is now woven into the biology of aging, metabolism, autophagy and inflammation — no longer a niche antiviral curiosity but a hub connecting cellular damage to systemic inflammatory tone.^[2] In that framing, cGAS-STING is not the whole of inflammaging, but it is one of its most tractable engines.

Can it be switched off? What the interventions show

If an overactive DNA alarm drives aging inflammation, the obvious idea is to quieten it. Research is moving along two broad routes.

The first is direct STING inhibition. In the 2023 mouse work, pharmacological STING blockade was the tool that produced the anti-inflammatory and functional benefits.^[1] Drug discovery has since expanded: a 2024 study in Advanced Science used an AI-guided screen to identify ginkgetin, a compound from Ginkgo biloba, as a direct STING inhibitor that reduced cellular senescence and improved multiple tissues in aging mice.^[6] A 2025 review in International Immunopharmacology surveys the growing pipeline of cGAS-STING-targeting agents being explored for age-related neurodegenerative disease.^[7] Promising — but every one of these is preclinical or early-stage, and none is a validated human anti-aging therapy.

The second route is more indirect and, arguably, more physiological: fix the upstream leak rather than silencing the alarm. Because much of the offending DNA comes from failing mitochondria, improving mitophagy — the selective clearance of damaged mitochondria — should reduce cytosolic mtDNA before cGAS ever sees it. A 2024 study in Nature Communications tested exactly this: inducing mitophagy with urolithin A in old mice lowered cytosolic mtDNA, attenuated cGAS-STING activation and improved neurological function.^[3] Separately, a 2021 study in PNAS found that boosting NAD+ with nicotinamide riboside reduced neuroinflammation in an Alzheimer's mouse model partly through a cGAS-STING-dependent mechanism, tying a popular longevity molecule to this same pathway.^[4]

Honest caveats

The enthusiasm needs boundaries. First, and most important: the causal, benefit-showing evidence is overwhelmingly from mice and cell culture. The 2023 Nature study used human senescent cells and tissues for parts of its work, but the functional-improvement results — the ones that matter for a claim about aging — came from mouse models.^[1] Mouse inflammation biology does not always translate to humans, and many anti-inflammatory strategies that rejuvenated mice have disappointed in people.

Second, cGAS-STING exists for a reason. It is a frontline defence against viruses and other pathogens, and chronically blocking it could plausibly blunt antiviral immunity or tumour surveillance. A drug that calms inflammaging but leaves an older person more vulnerable to infection would be a poor trade. Any real therapy will have to thread that needle, likely with careful dosing or tissue-specific targeting rather than blanket suppression.

Third, none of the compounds discussed here is an approved anti-aging treatment, and that emphatically includes the over-the-counter ones. Taking a Ginkgo biloba supplement is not a validated way to inhibit STING in your tissues; the ginkgetin study isolated and characterised a specific molecule in a controlled model, which is a very different thing from a capsule bought online.^[6] The urolithin A and NAD+ links to this pathway are mechanistically interesting but do not by themselves prove a human anti-aging effect.

What is solid is the biology: aging cells leak DNA, that DNA trips an ancient immune sensor, and the resulting chronic inflammation appears to actively drive tissue decline rather than passively mark it. That reframing — from inflammaging as a vague blood signature to a specific, druggable pathway with a clear upstream cause — is why cGAS-STING has become one of the most closely watched targets in longevity science. Whether it becomes a therapy is a question the human trials still have to answer.